Luminex respiratory panel cleared
This article was originally published in The Gray Sheet
Executive Summary
Toronto-based Luminex Molecular Diagnostics Jan. 3 obtains 510(k) clearance and launches its xTAG Respiratory Viral Panel, which detects 12 viruses and subtypes that are responsible for more than 85% of respiratory viral infections. xTAG RVP yields results in 10 hours and is the first test for detecting and differentiating influenza A subtypes H1 and H3, and for detecting human metapneumovirus. The test also detects influenza B; respiratory syncytial virus A and B; andenovirus; parainfluenza 1, 2 and 3; and rhinovirus
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.